Search

Oritavancin

[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections.

SGN-15

SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. … Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.

Ethinamate

Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient.

TRGFT-201

[L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … reconstitution and to improve chronic graft-versus-host disease-free survival, in adults with hematological malignancies.

Dodecyldimethylamine N-oxide

Mexiletine

Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

Telbivudine

Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.

LY2275796

LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

Chromous sulfate

Metamfetamine

It is a scheduled drug in most countries due to its high potential for addiction and abuse.